M. Yair Levy, M.D. | Texas Oncology

Dr. Moshe Yair Levy

Claim this profile

Texas Oncology - Sammons

Studies Chronic Illness
Studies Chronic Myelogenous Leukemia
8 reported clinical trials
17 drugs studied

Area of expertise

1

Chronic Illness

Moshe Yair Levy has run 2 trials for Chronic Illness. Some of their research focus areas include:

T315I negative
BCR-ABL1 positive
T315I positive
2

Chronic Myelogenous Leukemia

Moshe Yair Levy has run 2 trials for Chronic Myelogenous Leukemia. Some of their research focus areas include:

T315I negative
BCR-ABL1 positive
T315I positive

Affiliated Hospitals

Image of trial facility.

Texas Oncology - Sammons

Image of trial facility.

Baylor Scott & White Health

Clinical Trials Moshe Yair Levy is currently running

Image of trial facility.

Tagraxofusp + Venetoclax + Azacitidine

for Acute Myeloid Leukemia

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy.

Recruiting

1 award

Phase 2

10 criteria

Image of trial facility.

Selinexor + R-GDP

for Lymphoma

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified in Phase 2) versus standard R-GDP + matching placebo, for up to 6 cycles (21-day per cycle), followed by placebo or 60 mg selinexor single agent continuous therapy for those who have reached partial or complete response.

Recruiting

0 awards

Phase 2 & 3

9 criteria

More about Moshe Yair Levy

Clinical Trial Related

3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Moshe Yair Levy has experience with

  • Placebo
  • Ianalumab
  • Dexamethasone
  • Cisplatin
  • Placebo Matching For Selinexor (continuous Therapy)
  • Rituximab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Moshe Yair Levy specialize in?

Is Moshe Yair Levy currently recruiting for clinical trials?

Are there any treatments that Moshe Yair Levy has studied deeply?

What is the best way to schedule an appointment with Moshe Yair Levy?

What is the office address of Moshe Yair Levy?

Is there any support for travel costs?